Literature DB >> 24808021

Paraparetic Guillain-Barré syndrome.

Bianca van den Berg1, Christiaan Fokke1, Judith Drenthen1, Pieter A van Doorn1, Bart C Jacobs2.   

Abstract

OBJECTIVE: To define the clinical and diagnostic characteristics of paraparetic Guillain-Barré syndrome (GBS) with weakness restricted to the legs, compared with the classic quadriparetic GBS.
METHODS: Prospectively collected data from a cohort of 490 patients with GBS, previously involved in therapeutic or clinical studies, were used to define the demography, clinical presentation, diagnostic investigations, and clinical course in patients with paraparesis during a 6-month follow-up.
RESULTS: Forty patients (8%) presented with a paraparesis without weakness of arms and hands. In 29 patients (73%), normal strength of upper extremities persisted during the follow-up period. Patients with paraparesis compared to patients with quadriparesis had a milder form of GBS, with less frequent cranial nerve involvement and less severe leg weakness, despite the fact that the majority of these patients were unable to walk unaided. Median time between onset of weakness and study entry was 6 days (interquartile range 4-11 days) for patients with paraparesis compared with 5 days (interquartile range 3-8 days) for patients with quadriparesis (p = 0.031). Fifty percent of patients with paraparesis presented with arm sensory deficits and 73% had reduced or absent arm reflexes. Nerve conduction studies demonstrated arm nerve involvement in 89% of these patients. At 6 months of follow-up, 98% of patients with paraparesis were able to walk unaided compared with 81% of the patients with quadriparesis (p = 0.008). There was no association between paraparesis and age, sex, or preceding infections.
CONCLUSIONS: Paraparesis is an atypical clinical presentation or subform of GBS in which the diagnosis is usually supported by the presence of sensory deficits, reduced reflexes, or abnormal nerve conduction of the arms.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Year:  2014        PMID: 24808021     DOI: 10.1212/WNL.0000000000000481

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.

Authors:  Yusuf A Rajabally
Journal:  Neurotherapeutics       Date:  2022-06-01       Impact factor: 6.088

2.  Neurological Complications during Treatment of Middle East Respiratory Syndrome.

Authors:  Jee Eun Kim; Jae Hyeok Heo; Hye Ok Kim; Sook Hee Song; Sang Soon Park; Tai Hwan Park; Jin Young Ahn; Min Ky Kim; Jae Phil Choi
Journal:  J Clin Neurol       Date:  2017-07       Impact factor: 3.077

3.  Diagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteria.

Authors:  Joyce Roodbol; Marie-Claire Y de Wit; Bianca van den Berg; Vivienne Kahlmann; Judith Drenthen; Coriene E Catsman-Berrevoets; Bart C Jacobs
Journal:  J Neurol       Date:  2017-03-01       Impact factor: 4.849

4.  Motor lumbosacral radiculopathy in HIV-infected patients.

Authors:  Kaminie Moodley; Pierre L A Bill; Vinod B Patel
Journal:  South Afr J HIV Med       Date:  2019-10-28       Impact factor: 2.744

5.  Asymmetric limb weakness in Guillain-Barré syndrome: Three case reports.

Authors:  Ming Hu; Xiang Li; Hiu Yi Wong; Xun-Gang Feng; Yu-Zhong Wang; Guo-Rong Zhang
Journal:  World J Clin Cases       Date:  2022-02-26       Impact factor: 1.337

6.  Atypical Guillain-Barre syndrome with T6 sensory level.

Authors:  Osamah Al-Ameen; Mohanad Faisal; Salma Mustafa; Mohammed Alhatou
Journal:  Clin Case Rep       Date:  2022-10-08

7.  Paraparetic Variant of Guillain-Barré Syndrome in First 24 Hours of Postpartum Period: A case report.

Authors:  Danah Aljaafari; Noman Ishaque
Journal:  Sultan Qaboos Univ Med J       Date:  2020-06-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.